The effect of repeated intravenous and oral doses of molsidomine (N-carboxy-3-morpholino-sydnonimine-ethylester) on plasma renin activity and plasma catecholamine levels in conscious dogs
- 1 March 1983
- journal article
- research article
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 78 (2) , 193-202
- https://doi.org/10.1007/bf01906672
Abstract
The responses of plasma renin activity (PRA) and plasma catecholamine levels to molsidomine, administered both intravenously and orally, were investigated in conscious trained dogs. Intravenous administration of molsidomine at increasing dosage up to 0.4 mg/kg with a constant dose interval of 4 hours did not lead to a sustained increase in PRA. By contrast, a significant increase in PRA was still present after 4 hours on administration of 0.4 mg/kg molsidomine by the oral route. This longer-lasting increase in PRA following oral administration is discussed in relation to the conversion of molsidomine to an active metabolite in the liver. A reduction of dose interval to 3 hours or less led to a marked cumulative increase in PRA. It appears that substances acting via venous pooling lead to persistent activation of the renin angiotensin aldosterone system (RAA system), which counteracts its primary therapeutic effect. A slight increase in plasma noradrenaline levels was observed in response to repeated oral administration of 0.4 mg/kg molsidomine at a dose interval of 2 hours, indicating participation of the sympathetic nervous system in the counterregulatory process. Die Wirkung intravenöser und peroraler Gaben von Molsidomin auf die Plasmareninaktivität (PRA) und die Plasmakatecholaminspiegel wacher Hunde wurde untersucht. Intravenöse Verabreichung von Molsidomin in einer Dosierung bis zu 0,4 mg/kg bei einem gleichbleibenden Dosisintervall von 4 Stunden führte zu keinem langanhaltenden Anstieg der PRA. Im Gegensatz dazu war nach peroraler Verabreichung von 0,4 mg/kg Molsidomin nach 4 Stunden die PRA noch deutlich erhöht. Der relativ stärkere Anstieg der PRA auf orale Gabe wird mit Bezugnahme auf den Abbau von Molsidomin zu einem aktiven Metaboliten in der Leber diskutiert. Verkürzung des Dosisintervalls auf 3 Stunden und weniger führte zu einem kumulativen PRA-Anstieg. Es ist anzunehmen, daß Substanzen, die venöses Pooling verursachen, zu einer andauernden Aktivierung des Renin-Angiotensin-Aldosteron-Systems (RAA-System) führen, welche dem ursprünglichen therapeutischen Effekt entgegenwirkt. Der geringe Anstieg der Plasmanoradrenalinwerte, der nach peroraler Gabe von 0,4 mg/kg Molsidomin bei einem Dosisintervall von 2 Stunden beobachtet wurde, deutet die Mitbeteiligung des Sympathischen Nervensystems bei der Gegenregulation an.Keywords
This publication has 24 references indexed in Scilit:
- Oral Isosorbide dinitrate in angina pectoris: Comparison of duration of action and dose-response relation during acute and sustained therapyThe American Journal of Cardiology, 1982
- Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy.Circulation, 1981
- Comparison of the Effects of Nitroglycerin Administered to Rats by Different RoutesJournal of Cardiovascular Pharmacology, 1981
- The effect of single and repeated oral doses of isosorbide dinitrate on plasma renin activity and plasma catecholamine levels in conscious dogsBasic Research in Cardiology, 1980
- Hemodynamic and myocardial effects of long-lasting venodilation in the conscious dogBasic Research in Cardiology, 1978
- Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole rangeLife Sciences, 1976
- The renin-angiotensin-aldosterone system in congestive failure in conscious dogs.Journal of Clinical Investigation, 1976
- Reflex suppression of renin secretion during distention of cardiopulmonary receptors in dogs.Circulation Research, 1976
- Altered renin release and propranolol potentiation of vasodilatory drug hypotension.Journal of Clinical Investigation, 1975
- Biotransformation of Molsidomine (N-Ethoxycarbonyl-3-morpholinosydnonimine), a New Anti-anginal Agent, in RatsXenobiotica, 1974